Navigation Links
Inhibiting prostate cancer without disturbing regular body processes
Date:8/9/2010

This release is available in French.

Inhibiting prostate cancer without disturbing regular body processes Researchers explain how a facultative enzyme governs tumour growth

A kinase is a type of enzyme the body uses to regulate the functions of the proteins required for cell growth and maintenance, and researchers have discovered that one in particular plays a key role in developing prostate cancer. "It's known as Mnk, and although it appears not to be essential for normal cell maintenance, it's important for cancer growth" said Dr. Luc Furic, a postdoctoral researcher working with Dr. Nahum Sonenberg at McGill University's Goodman Cancer Research Centre and Department of Biochemistry.

This is a very significant finding because the body's chemical processes are highly complex and interrelated, meaning that targeting one cause of cancer often involves affecting the body's normal functions. An important part of cancer research is about trying to find processes that can be inhibited or stopped without causing damages to normal tissue.

The chemical process Mnk uses is known as phosphorylation, and this process activates or inactivates the body's proteins, controlling mechanisms that can cause disease. In this case, Mnk works with a protein known as eIF4E to synthesize proteins in the cell.

Researchers at the Centre hospitalier de l'Universit de Montral Research Centre (CRCHUM), Universit de Montral and McGill University engineered mice that were able to block the phosphorylation process of this protein, and discovered that these mice became resistant to prostate cancer growth. "The PTEN gene and its protein act as a tumour suppressor," explained Dr. Fred Saad, researcher at the CRCHUM and at Universit de Montral's Department of Surgery. "By removing this gene in the mouse prostate, we were able to study eIF4E's effect on cell growth."

The research is directly related to humans, because PTEN is frequently mutated in human prostate cancer. Studies on cancer patients have confirmed eIF4E's involvement.

The task ahead will be to find a specific and selective pharmacological inhibitor of Mnks. Although some inhibitors are used for research purposes, these inhibitors are not highly specific to this kinase.


'/>"/>

Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related medicine news :

1. Inhibiting fatty acids in immune cells decreases atherosclerosis risk
2. Advance Toward Test for Aggressive Prostate Cancer
3. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
4. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
5. Few differences in outcomes between open and laparoscopic prostate surgery
6. Two Surgical Methods Equally Successful for Prostate Cancer
7. Genetic Mutation Linked to Prostate Cancer in Blacks
8. Statins May Benefit Prostate Cancer Patients
9. Demand For Mobile Prostate Cancer Brachytherapy Vendor Programs Continues Into 2010
10. Be a Star Athlete in the Fight Against Prostate Cancer
11. Do men with early prostate cancer commit suicide more frequently?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Airway ... new partnership with the highly regarded and well renowned Asian distributor, Discovery Sleep. ... & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s presence ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... imaging practices, is seeking candidates to serve on its Accreditation and Standards ... , “RadSite’s ultimate mission is improving image quality and reducing patient radiation ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... to experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become ... privilege to help my numerous clients over the years with all their dental needs,” ...
(Date:4/21/2017)... ... ... During April 21-23, Super-Sod will join the vendor market of the Sacred Heart ... from the avid gardener to the landscape admirer — during the three-day schedule. , ... grand venue, and we are certainly looking forward to participating in this year’s festival,” ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... Service Provider, announces a significant bandwidth upgrade infrastructure service to Tele-Media Solutions. ... Solutions. One of IFN’s consortium member-owners, Tele-Media Solution’s protect transport with 3GB ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: